Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients

Figures & data

Table 1 Clinical characteristics of the patient population (N=65)

Variable	Number
Gender
Male	37
Female	28
Age, years
Median	62
<65	47
≥65	18
Smoking status
Never	31
Former/current	34
Pathological stage after surgery
I + II	33
IIIA	32
EGFR status
Mutation	28
Wild type	24
Unknown	13
PD-L1 expression in resected samples
Positive	28
Negative	37
PD-L1 expression in recurrence samples
Positive	36
Negative	29

Abbreviations: EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1.

Table 2 Clinical characteristics of patients with altered PD-L1 expression

Case	Gender/age (years)	Pathological stage	Smoking status	PD-L1 expression		Disease-free survival, months	Overall survival, months
				Resected samples	Recurrence samples
1	M/61	IIIA	Former	Positive	Negative	11.5	37.9
2	M/55	IIIA	Never	Positive	Negative	20.0	45.5
3	M/67	IIIA	Former	Negative	Positive	26.0	55.0
4	M/59	IIB	Former	Negative	Positive	19.0	38.0
5	M/52	IIIA	Current	Negative	Positive	7.0	21.0
6	M/71	IB	Former	Negative	Positive	39.0	57.2
7	F/60	IIIA	Never	Negative	Positive	12.5	43.0
8	M/63	IIA	Never	Negative	Positive	33.0	49.0+
9	F/66	IB	Never	Negative	Positive	41.5	61.6+
10	M/51	IIIA	Current	Negative	Positive	16.0	36.5
11	F/38	IIB	Current	Negative	Positive	13.3	35.2
12	F/51	IIIA	Never	Negative	Positive	14.5	55.4

Abbreviation: PD-L1, programmed death-ligand 1.

Table 3 Correlation between PD-L1 expression and clinical characteristics

Variable	Resected samples			Recurrence samples
	PD-L1 positive	PD-L1 negative	P-value	PD-L1 positive	PD-L1 negative	P-value
Gender			0.64			0.45
Male	15	22		19	18
Female	13	15		17	11
Age (years)			0.21			0.049
<65	18	29		22	25
≥65	10	8		14	4
Smoking status			0.49			0.56
Never	12	19		16	15
Former/current	16	18		20	14
Pathologic stage			0.16			0.44
I + II	17	16		NA	NA	NA
IIIA	11	21		NA	NA	NA
EGFR mutation			0.086
Yes	16	12		NA	NA	NA
No	8	16		NA	NA	NA

Abbreviations: EGFR, epidermal growth factor receptor; NA, not applicable; PD-L1, programmed death-ligand 1.

Figure 1 Progression-free survival of EGFR-TKIs in EGFR-mutant patients according to the status of PD-L1 expression in recurrent samples.

Abbreviations: EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1; TKIs, tyrosine kinase inhibitors.

Figure 2 Comparison of disease-free survival based upon the status of PD-L1 expression in resection lung adenocarcinoma samples.

Abbreviation: PD-L1, programmed death-ligand 1.